NIH to honor IGB faculty member with innovator award

Dr. Douglas A. Mitchell, IGB faculty member and assistant professor in the Department of Chemistry, will pursue a generalized, toxin-disabling strategy to fight bacterial infectious disease

Douglas A. Mitchell, IGB faculty member in the Mining Microbial Genomes for Novel Antibiotics research theme and assistant professor in the Department of Chemistry, is a recipient of the 2011 National Institutes of Health Director's New Innovator Award. The award recognizes bold ideas from some of the nation's most promising new scientists.

The $1.5 million award, given over a period of five years, supports young investigators who have proposed exceptionally creative research ideas that have the potential to produce important medical advances.

Mitchell uses chemical methods to study the mechanisms that contribute to bacterial virulence and antibiotic resistance. His current studies focus on the thiazole/oxazole-modified microcins, a class of microbial compounds with profound structural and functional diversity. While some of these compounds have antibiotic or anticancer activity, others are disease-promoting toxins.

Mitchell's lab is developing a strategy to disrupt toxin biosynthesis in a number of bacterial pathogens. He predicts that this approach will lead to drugs that combat pathogenic microbes without disturbing the symbiotic bacteria that are essential to proper human physiological function. This new class of antimicrobial compounds will be less likely to select for antibiotic resistance in the targeted pathogens than drugs now used, he said.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New biomarker testing protocol could shorten antibiotic treatment for sepsis